ATRA
Atara Biotherapeutics, Inc.
Key Financials
Revenue
$120.8M
↓ 6.3%
Net Income
$32.7M
↑ 138.3%
Total Assets
$20.2M
↓ 81.5%
Total Liabilities
$58.7M
↓ 71.5%
EPS (Diluted)
$2.57
↑ 122.5%
Cash & Equivalents
$8.5M
↓ 66.1%
Operating Income
$35.9M
↑ 143.0%
Shareholders' Equity
$-38502000.00
↑ 60.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/26/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 3 | 6/15/2026 | View on SEC |
| S-8 | 6/12/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
| 4 | 5/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ATRA |
| Company Name | Atara Biotherapeutics, Inc. |
| CIK | 1604464 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 805-623-4211 |